admedus cardiocel® 6 year data

SX ANNOUNCEMENT

ADMEDUS CARDIOCEL®
6 YEAR DATA
? CardioCel®
shows no calcification after 6 years
? Extension study continues to show no calcification with CardioCel®

? All patients showing no calcification and no need for follow up surgery

Brisbane, Australia, 28th
April, 2014
Admedus (ASX: AHZ) today announced that 6 years post implantation CardioCel®

continues to show no level of calcification or any other issues.
The first patient from the Phase II study has had their 6 year follow up and the results
show there is still no detectable calcification of CardioCel®
with no “re-do” surgery
required and no other issues. The patient was initially implanted at 3 weeks of age and
has successfully reached their 6
th
birthday with no implant issues.
“This is great progress for patients in not having to have additional surgeries and it
represents huge potential for the future treatment of congenital heart disease and
other cardiac defects” said Admedus CEO Mr Lee Rodne.
All other patients in the study continue to show no signs of calcification or follow up
surgeries after 3 to 5 years. The company anticipates continued data from the ongoing
monitoring of these patients.
“We have always believed that CardioCel®
has enormous potential in the future of
cardiac surgery and this data highlights the longer term benefits of using CardioCel®

and its superiority over alternatives” said Mr Rodne
Patients from the Phase II study are examined for calcification and overall patient
health annually.
Earlier this year Admedus received FDA clearance for CardioCel®
and last year
CardioCel® was approved in Europe under a CE Mark.